Categories
Lung Cancer

The CheckMate 816 Trial: The Success of Adjuvant NSCLC Therapies – Lung Cancer OncTalk 2022 [Video]

The CheckMate 816 Trial: The Success of Adjuvant NSCLC Therapies – Lung Cancer OncTalk 2022

This video series is from our live Lung Cancer OncTalk event held annually. We bring together a talented group of oncologists to discuss emerging treatment options, clinical trial data, and to answer audience questions.

In this video, Dr. Julia Rotow discusses the CheckMate 816 trial and looks at successful adjuvant therapies for NSCLC.

For the full agenda, https://cancergrace.org/onctalk-2022-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2022-faculty.

A huge thank you to our sponsor! #takedaoncology

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Watch/Read More
Categories
Lung Cancer

SPOTLIGHT: zolbetuximab and m-FOLFOX6 in CLDN18.2+, HER2- GEJ cancer [Video]

Kohei Shitara, MD, National Cancer Center Hospital East, Chiba, Japan, provides an overview of findings from the Phase III SPOTLIGHT trial (NCT03504397), which assessed zolbetuximab in patients with CLDN18.2-positive, HER2-negative, locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Zolbetuximab is a first-in-class monoclonal antibody targeting CLDN18.2, and patients were given modified-FOLFOX6 with or without zolbetuximab. 2735 patients were recruited, and addition of zolbetuximab significantly improved progression-free survival and overall survival. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.